With the discovery of antibiotics, they have greatly influenced medical practice, saving millions of lives from deadly infections every year. However, due to the misuse of antibiotics, the phenomenon of antimicrobial resistance is on the rise. The lack of effective antibiotics coupled with the spread of resistance genes are pressing global health problems. If these problems are not properly addressed and new antibiotics are not developed, antibiotic resistance will become the leading cause of mortality by 2050. Natural compounds are an important source of new antibiotics in modern medicine, with a substantial impact on global health. Antarctica is a rich source of new microbial species with high potential for biotechnological applications, including the development of antimicrobial compounds. The AntarcticPharma project is centred on the strain Janthinobacterium sp. ROICE36 isolated from Antarctica by Romanian researchers. The genus Janthinobacterium is a promising source for the identification of novel antimicrobial compounds with an effect even against important multi-drug resistant pathogens. The implementation of the AntarcticPharma project will lead to: (i) characterisation of a novel strain of Janthinobacterium in terms of carbon source utilisation and enzyme activity; (ii) sequencing and characterisation of the genome of strain ROICE36 as an important resource for future biotechnological applications; (iii) a method to culture the ROICE36 strain in order to obtain an increased amount of biomass; (iv) a method to obtain a bacterial extract using the ROICE36 strain, whose antimicrobial efficiency will be tested against multi-drug resistant pathogens isolated from environmental and clinical settings in Romania. Stakeholders of the AntarcticPharma project include researchers, clinicians and representatives of the pharmaceutical industry interested in the discovery of new antimicrobial compounds.